Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-b
neutralizing antibody responses and T cell reactivity ag

EBioMedicine

75, 103761

DOI: 10.1016/j.ebiom.2021.103761

Citation Report

#	Article	IF	Citations
1	Human vaccines & immunotherapeutics: news. Human Vaccines and Immunotherapeutics, 2024, 17, 4703-4704.	1.4	1
2	Heterologous ChAdOx1-nCoV19â€“BNT162b2 vaccination provides superior immunogenicity against COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 1207-1209.	5.2	5
3	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	6.3	430
4	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. Transplantation and Cellular Therapy, 2021, 27, 973-987.	0.6	25
6	COVIDâ€19 vaccines mixâ€andâ€match: The concept, the efficacy and the doubts. Journal of Medical Virology, 2022, 94, 1294-1299.	2.5	69
7	Heterologous primeâ€“boost strategies for COVID-19 vaccines. Journal of Travel Medicine, 2021, , .	1.4	37
8	Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses. Clinical Infectious Diseases, 2022, 75, e653-e661.	2.9	16
9	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. BMC Medicine, 2022, 20, 29.	2.3	20
11	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	6.3	161
12	Humoral immune response after different SARS-CoV-2 vaccination regimens. BMC Medicine, 2022, 20, 31.	2.3	47
13	Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. Infection, 2022, , 1.	2.3	15
14	Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomedicine and Pharmacotherapy, 2022, 147, 112650.	2.5	30
15	Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. PLoS Medicine, 2021, 18, e1003874.	3.9	30
16	Adopting an heterologous prime-boost strategy in COVID-19 vaccination, the need for locally generated evidence in Africa. Pan African Medical Journal, 2022, 41, 148.	0.3	1
17	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110566.	0.7	13
18	Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19. Viruses, 2022, 14, 380.	1.5	4
19	Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines, 2022, 10, 359.	2.1	11
20	SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore. Vaccines, 2022, 10, 331.	2.1	17

#	Article	IF	Citations
21	Revival of the heterologous primeâ€boost technique in <scp>COVID</scp>â€19: An outlook from the history of outbreaks. Health Science Reports, 2022, 5, e531.	0.6	7
24	Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. Frontiers in Immunology, 2022, 13, 797589.	2.2	30
25	Current perspectives regarding SARSâ€CoVâ€2 vaccination inÂchronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 313-319.	0.8	3
27	Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review. , 2022, 39, 89-97.		1
28	Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Journal of the Formosan Medical Association, 2022, 121, 766-777.	0.8	22
29	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	10
30	American College of Rheumatology Guidance for <scp>COVID</scp>â€19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis and Rheumatology, 2022, 74, e21-e36.	2.9	49
31	Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. Vaccines, 2022, 10, 649.	2.1	6
32	Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination. Frontiers in Immunology, 2022, 13, .	2.2	16
33	Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infectious Diseases of Poverty, 2022, 11, 53.	1.5	25
34	Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2. Vaccines, 2022, 10, 788.	2.1	2
35	Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron. IScience, 2022, 25, 104473.	1.9	19
36	Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study. BMC Infectious Diseases, 2022, 22, .	1.3	9
38	Acceptance and willingness to pay under the different COVID-19 vaccines: A contingent valuation method. Research in Social and Administrative Pharmacy, 2022, , .	1.5	1
39	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Frontiers in Immunology, 0, 13, .	2.2	4
40	Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico. PLoS ONE, 2022, 17, e0269032.	1.1	4
41	Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression. Viruses, 2022, 14, 1308.	1.5	1
42	Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerging Microbes and Infections, 2022, 11, 1910-1919.	3.0	27

#	Article	IF	Citations
43	Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine. Vaccines, 2022, 10, 929.	2.1	3
44	Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. BMJ, The, 0, , e070483.	3.0	7
45	Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	20
46	Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. Infectious Disease Reports, 2022, 14, 537-546.	1.5	23
47	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Frontiers in Immunology, 0, 13, .	2.2	16
48	Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	9
49	Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study. Vaccines, 2022, 10, 1241.	2.1	1
50	Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. Microbiology Spectrum, 2022, 10, .	1.2	7
52	The current status of COVID-19 vaccines. A scoping review. Drug Discovery Today, 2022, 27, 103336.	3.2	7
53	Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Frontiers in Microbiology, 0, 13, .	1.5	12
55	Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELDâ„¢ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. Frontiers in Immunology, 0, 13, .	2.2	14
56	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. EBioMedicine, 2022, 85, 104294.	2.7	11
57	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Frontiers in Immunology, 0, 13, .	2.2	5
58	Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru. PLoS ONE, 2022, 17, e0268419.	1.1	4
60	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS ONE, 2022, 17, e0263861.	1.1	12
61	Impaired neutralizing antibodies and preserved cellular immunogenicity against SARS-CoV-2 in systemic autoimmune rheumatic diseases. Npj Vaccines, 2022, 7, .	2.9	3
62	The â€œvaccineâ€•hubbub: Viral load comparisons of SARSâ€CoVâ€2 Delta and Omicron variants against different vaccineâ€“booster vaccine combinations. Journal of Medical Virology, 2023, 95, .	2.5	0
63	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines, 2022, 10, 1926.	2.1	29

#	Article	IF	Citations
64	Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19. Vaccines, 2022, 10, 1864.	2.1	6
65	American College of Rheumatology Guidance for <scp>COVID</scp>â€19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis and Rheumatology, 2023, 75, .	2.9	45
66	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 1948.	2.1	3
67	In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant. Frontiers in Immunology, 0, 13, .	2.2	3
68	Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations. Annals of Laboratory Medicine, 2023, 43, 290-294.	1.2	1
69	COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia. HemaSphere, 2023, 7, e811.	1.2	6
70	Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine. EBioMedicine, 2023, 88, 104435.	2.7	20
71	Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study. Vaccines, 2023, 11, 56.	2.1	4
72	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. Vaccines, 2023, 11, 42.	2.1	5
73	The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster. Infection and Drug Resistance, 0, Volume 15, 7811-7821.	1.1	2
74	Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. Frontiers in Public Health, 0, 10, .	1.3	2
75	Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?. IJID Regions, 2023, 7, 159-163.	0.5	1
76	Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine, 2023, 41, 1925-1933.	1.7	11
77	Identification of genes related to immune enhancement caused by heterologous ChAdOx1â€“BNT162b2 vaccines in lymphocytes at single-cell resolution with machine learning methods. Frontiers in Immunology, 0, 14, .	2.2	4
78	Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. EBioMedicine, 2023, 89, 104475.	2.7	4
79	Development of biological and other healthcare products. , 2023, , 575-615.		0
80	Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. Viruses, 2023, 15, 844.	1.5	3
81	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. Vaccine, 2023, 41, 3003-3010.	1.7	1

#	Article	IF	Citations
83	Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
94	Antibody titers of individuals vaccinated forÂCOVID-19: A systematic review. Journal of Biosciences, 2023, 48, .	0.5	0